Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
about
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsIn situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancerA comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancerAndrogen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.Advanced prostate cancer: treatment and patient-centred care.Androgen deprivation therapy: past, present and future.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Choosing a prostate cancer drug.Prostate cancer patients' report on communication about endocrine therapy and its association with adherence.Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.
P2860
Q26824762-309F4C36-D9E2-47D7-BD61-D8F4EAAD6D5BQ28390899-D8BDAF79-EA1E-486F-BB44-E62E21B70AE4Q36120758-9B3F30D2-B3DA-48D3-BF03-06E1D647387CQ36269807-53CA98F2-8698-4D12-B80B-A54325CB32CDQ36557840-39B1160C-C9F5-4DD8-9F4B-313933FC5239Q37708169-E8FF1B81-6C2E-4D98-B217-C437CBD08BF4Q37999367-89065E36-8DD5-40C2-B3DE-4ECF21CE9632Q38016530-4787DC68-8752-45E4-AFEF-99A2EE7CBD03Q38023124-896FE3D0-65D1-4521-A9A2-D124CE246907Q38207463-92A6BD86-5733-4458-BD59-328005ACB458Q38247423-A5812545-1414-4E21-AF7F-61B21697F1D2Q40400790-542BD4A9-F2FA-45F6-80F6-B6B25C3AEF85Q40927190-3E3FC50D-076F-451A-8807-54C35E954CC2Q41669642-AC6C213C-682D-47E8-B419-2172003B8133Q47825566-5C5B8EAD-B28D-4880-A8E1-D79124B63784
P2860
Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Androgen deprivation therapy a ...... e cancer: recent developments.
@en
Androgen deprivation therapy a ...... e cancer: recent developments.
@nl
type
label
Androgen deprivation therapy a ...... e cancer: recent developments.
@en
Androgen deprivation therapy a ...... e cancer: recent developments.
@nl
prefLabel
Androgen deprivation therapy a ...... e cancer: recent developments.
@en
Androgen deprivation therapy a ...... e cancer: recent developments.
@nl
P2860
P921
P356
P1476
Androgen deprivation therapy a ...... e cancer: recent developments.
@en
P2860
P2888
P304
P356
10.1038/BJC.2011.385
P407
P577
2011-10-18T00:00:00Z
2011-11-22T00:00:00Z